Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome

Journal of Clinical Oncology

Volumn 23, Issue 19, 2005, Pages 4381-4389

  Dimopoulos, Meletios A ^a   Souliotis, Vassilis L ^a   Anagnostopoulos, Athanasios ^a   Papadimitriou, Christos ^a   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA ACTIN; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PROCARBAZINE; PROTEIN P53; ACTIN;

AGED; ARTICLE; CANCER REGRESSION; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MEGADOSE; FEMALE; GENE MUTATION; GENETIC DAMAGE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MALE; MYELOMA; ONCOGENE N RAS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TUMOR SUPPRESSOR GENE; ADULT; DNA ADDUCT; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; ONCOGENE RAS; TREATMENT OUTCOME;

ACTINS; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; FEMALE; GENES, P53; GENES, RAS; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 22344450423     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.385     Document Type: Article

References (41)

1. Osborne MR, Wilman DE, Lawley PD: Alkylation of DNA by the nitrogen mustard bis(2-chloroethyl)methylamine. Chem Res Toxicol 8:316-320, 1995
2. Lawley PD, Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res 355:13-40, 1996
3. Ringborg U, Hansson J, Jungnelius U, et al: Melphalan-induced DNA cross-linking and inhibition of DNA and RNA synthesis in human melanoma and lymphoblast cells. Anticancer Res 10:297-301, 1990
4. Grant DF, Bessho T, Reardon JT: Nucleotide excision repair of melphalan monoadducts. Cancer Res 58:5196-5200, 1998
5. Dronkert ML, Kanaar R: Repair of DNA interstrand cross-links. Mutat Res 486:217-247, 2001
6. 6-alkylguanine DNA repair activity during continuous exposure to carcinogen. Proc Natl Acad Sci U S A 79:5499-5502, 1982
7. 6-methylguanine-DNA-methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 145:1-16, 1985
8. Arlett CF: Human DNA repair defects. J Inherited Metab Dis 9:69-84, 1986 (suppl 1)
9. Lehman AR: Xeroderma pigmentosum, Cockayne syndrome and ataxia-telangiectasia: Disorders relating DNA repair to carcinogenesis. Cancer Surv 1:93-118, 1982
10. Hanawalt PC: Heterogeneity of DNA repair at the gene level. Mutat Res 247:203-211, 1991
11. Mullenders LH, Vrieling H, Venema J, et al: Hierarchies of DNA repair in mammalian cells: Biological consequences. Mutat Res 250:223-228, 1991
12. Souliotis VL, Dimopoulos MA, Sfikakis PP: Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 9:4465-4474, 2003
13. Tilby MJ, Mewell DR, Viner C, et al: Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. Eur J Cancer 29A:681-686, 1993
14. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822-824, 1983
15. Palumbo A, Triolo S, Argentino C, et al: Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94:1248-1253, 1999
16. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 103:20-32, 2004
17. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT-European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
18. Nakajima-Iijima S, Hamada H, Reddy P, et al: Molecular structure of the human cytoplasmic beta-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci U S A 82:6133-6137, 1985
19. Kohn KW: Molecular mechanisms of crosslinking by alkylating agents and platinum complexes, in Sartorelli AC, Lazlo JS, Bertino JR (eds): Molecular Actions and Targets for Cancer Chemotherapy Agents. New York, NY, Academic Press Inc, 1981, pp 3-16
20. Reid BD, Walker IG: The response of mammalian cells to alkylating agents: II. On the mechanism of the removal of sulfur-mustard-induced cross-links Biochim Biophys Acta 179:179-188, 1968
21. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
22. Fan S, El-Deiry WS, Bae L, et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830, 1994
23. O'Connor PM, Jackman J, Jondle D, et al: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780, 1993
24. Lowe SW, Bodos S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
25. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
26. Rowley M, Liu P, Van Ness B: Heterogeneity in therapeutic response of genetically altered myeloma cells to interleukin 7, dexamethasone, doxorubicin, and melphalan. Blood 96:3175-3180, 2000
27. Spanswick VJ, Craddock C, Sekhar M, et al: Repair of DNA interstrand cross-links as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100:224-229, 2002
28. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
29. Ozols RF, Hogan WM, Young RC: Direct cloning of human ovarian cancer in soft agar: Clinical limitations and pharmacologic applications. Recent Results Cancer Res 94:41-50, 1984
30. Kaufmann M: Biochemical short-term predictive assay: Results of correlative trials in comparison to other assays. Recent Results Cancer Res 94:151-160, 1984
31. Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, et al: Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: Comparison with in vitro adduct formation. Cancer Res 50:7887-7894, 1990
32. Poirier MC, Reed E, Zwelling LA, et al: Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)-DNA adducts in cancer patients and animal models. Environ Health Perspect 62:89-94, 1985
33. Reed E, Yuspa SH, Zwelling LA, et al: Quantitation of cis-diamminedichloroplatinum(II) (Cisplatin)-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77:545-550, 1986
34. Reed E, Ozols RF, Tarone R, et al: Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A 84:5024-5028, 1987
35. 6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine. Carcinogenesis 12:285-288, 1991
36. 6-methylguanine in humans and rodents treated with procarbazine. Carcinogenesis 15:1675-1680, 1994
37. Parker RJ, Gill I, Tarone R, et al: Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 12:1253-1258, 1991
38. Panasci L, Henderson D, Torres-Garcia SJ, et al: Transport, metabolism and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res 48:1972-1976, 1988
39. Zwelling L, Michaels S, Schwartz H, et al: DNA crosslinking as an indicator of sensitivity and resistance of L1210 leukaemia cells to cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res 41:640-649, 1981
40. Sunters A, Springer CJ, Bagshawe KD, et al: The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis (2-chloroethyl)amino]benzoic acid. Biochem Pharmacol 44:59-64, 1992
41. Ferreira CG, Tolis C, Giaccone G, et al: p53 and chemosensitivity. Ann Oncol 10:1011-1021, 1999